AURA News and Press, Aura Biosciences Inc. From 03/23/22

Aura Biosciences press release (NASDAQ:AURA): Q4 net loss of $11.6M As of December 31, 2021, company had cash and cash equivalents totaling $149.1M. For further details see: Aura Biosciences reports Q4 results

On Track to Initiate Pivotal Trial in Choroidal Melanoma and Phase 1 Trial in Non-Muscle Invasive Bladder Cancer with AU-011 in 2H 2022 Orphan Drug Designation Granted to AU-011 by European Commission for the Treatment of Uveal Melanoma (Includes Choroidal Melanoma) Jo...

The European Commission has granted orphan drug designation to Aura Biosciences (NASDAQ:AURA) AU-011, a lead candidate for the treatment of uveal melanoma. The designation of uveal melanoma includes choroidal melanoma as well as melanomas of the iris and the ciliary body. Choroidal ...

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that the European Commission has granted Orphan Drug Designation to AU-011, its first VDC...

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced it will host a virtual Investor Day on Tuesday, March 22, 2022, from 11:00 a.m. to 12:30 ...

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the presentation of preclinical data for its first VDC product candidate, AU-011 which is...

The following slide deck was published by Aura Biosciences, Inc. in conjunction with this event. For further details see: Aura Biosciences (AURA) Investor Presentation - Slideshow

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer of Aura, will participate in the...

Company on Track to Initiate Phase 1 Clinical Trial in 2H 2022 Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the presentati...

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer of Aura, will participate in a f...